Recursion Pharmaceuticals (RXRX 0.02%), a biotech company focused on artificial intelligence (AI), went public in April 2021. This was before ChatGPT, before AI became the hottest ...

Some new investors pitched in to Recursion Pharmaceuticals Inc.'s $121 million series C financing, adding to the industry's vision of the importance of AI and machine learning.

Recursion on Tuesday held a webinar to discuss results from the Phase 1/2 study of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. The results were presented at an AACR Special ...

Recursion announces the close of a $121 million Series C financing to advance its machine learning-enabled approach to drug discovery and development.

Recursion Announces Promising Clinical Data on Lead AI-Based Drug Candidate for Brain Disease Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in ...

Recursion's AI-Powered Drug Revolution Recursion is a clinical-stage TechBio company that is fundamentally built upon the principles of artificial intelligence and machine learning.